Advertisement
UK markets closed
  • NIKKEI 225

    39,233.71
    +135.03 (+0.35%)
     
  • HANG SENG

    16,634.74
    -91.12 (-0.54%)
     
  • CRUDE OIL

    77.60
    +0.02 (+0.03%)
     
  • GOLD FUTURES

    2,040.90
    -8.50 (-0.41%)
     
  • DOW

    39,069.23
    -62.30 (-0.16%)
     
  • Bitcoin GBP

    43,075.51
    +2,299.88 (+5.64%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • NASDAQ Composite

    15,976.25
    -20.57 (-0.13%)
     
  • UK FTSE All Share

    4,190.80
    -11.96 (-0.28%)
     

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S
Novo Nordisk A/S

Bagsværd, Denmark, 1 February 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Liselotte Sofie Hyveled

 

2

Reason for the notification

 

a)

Position/status

Member of the Board of Directors

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Other transaction (transfer of shares in
accordance with Long Term Incentive programme)

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 0.00

2,028 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



2,028 shares
DKK 0.00

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Outside a trading venue

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Liselotte Sofie Hyveled

 

2

Reason for the notification

 

a)

Position/status

Member of the Board of Directors

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Other transaction (transfer of shares in
accordance with Long Term Incentive programme)

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 0.00

2,042 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



2,042 shares
DKK 0.00

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Outside a trading venue

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Lars Fruergaard Jørgensen

 

2

Reason for the notification

 

a)

Position/status

President and CEO

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Other transaction (transfer of shares in
accordance with Long Term Incentive programme)

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 0.00

131,760 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



131,760 shares
DKK 0.00

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Outside a trading venue

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Lars Fruergaard Jørgensen

 

2

Reason for the notification

 

a)

Position/status

President and CEO

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Other transaction (transfer of shares in
accordance with Long Term Incentive programme)

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 0.00

149,422 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



149,422 shares
DKK 0.00

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Outside a trading venue

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Maziar Mike Doustdar

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Other transaction (transfer of shares in
accordance with Long Term Incentive programme)

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 0.00

41,488 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



41,488 shares
DKK 0.00

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Outside a trading venue

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Maziar Mike Doustdar

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Other transaction (transfer of shares in
accordance with Long Term Incentive programme)

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 0.00

48,791 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



48,791 shares
DKK 0.00

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Outside a trading venue

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Maziar Mike Doustdar

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Sale of shares

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 756.84

2,166 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



2,166 shares
DKK 756.84

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Nasdaq Copenhagen

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Maziar Mike Doustdar

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Sale of shares

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 756.84

2,548 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



2,548 shares
DKK 756.84

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Nasdaq Copenhagen

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Ludovic Helfgott

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Other transaction (transfer of shares in
accordance with Long Term Incentive programme)

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 0.00

37,346 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



37,346 shares
DKK 0.00

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Outside a trading venue

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Ludovic Helfgott

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Other transaction (transfer of shares in
accordance with Long Term Incentive programme)

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 0.00

36,664 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



36,664 shares
DKK 0.00

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Outside a trading venue

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Ludovic Helfgott

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Sale of shares

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 756.84

11,620 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



11,620 shares
DKK 756.84

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Nasdaq Copenhagen

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Ludovic Helfgott

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Sale of shares

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 756.84

11,407 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



11,407 shares
DKK 756.84

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Nasdaq Copenhagen

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Karsten Munk Knudsen

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Other transaction (transfer of shares in
accordance with Long Term Incentive programme)

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 0.00

41,254 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



41,254 shares
DKK 0.00

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Outside a trading venue

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Karsten Munk Knudsen

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Other transaction (transfer of shares in
accordance with Long Term Incentive programme)

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 0.00

43,402 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



43,402 shares
DKK 0.00

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Outside a trading venue

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Douglas Langa

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Other transaction (transfer of shares in
accordance with Long Term Incentive programme)

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 0.00

41,488 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



41,488 shares
DKK 0.00

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Outside a trading venue

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Douglas Langa

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Other transaction (transfer of shares in
accordance with Long Term Incentive programme)

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 0.00

39,755 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



39,755 shares
DKK 0.00

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Outside a trading venue

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Douglas Langa

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Sale of shares

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 756.84

22,027 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



22,027 shares
DKK 756.84

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Nasdaq Copenhagen

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Douglas Langa

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Sale of shares

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 756.84

19,878 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



19,878 shares
DKK 756.84

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Nasdaq Copenhagen

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Douglas Langa

2

Reason for the notification

a)

Position/status

Executive Vice President, head of North America Operations

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer

a)

Name

Novo Nordisk A/S

b)

LEI

549300DAQ1CVT6CXN342

4

Details of the transaction(s)

a)

Description of the financial instrument,
type of instrument,

ADRs

 

Identification code

NVO

b)

Nature of the transaction

Purchase of ADRs

c)







Price(s) and volume(s)







 

 

 

 

 

Price(s)

Volume(s)

 

 

DKK 1,092.25

16.31 ADRs

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



16.31 ADRs
DKK 1,092.25

e)

Date of the transaction

2023-04-10

f)

Place of the transaction

New York Stock Exchange


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Douglas Langa

2

Reason for the notification

a)

Position/status

Executive Vice President, head of North America Operations

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer

a)

Name

Novo Nordisk A/S

b)

LEI

549300DAQ1CVT6CXN342

4

Details of the transaction(s)

a)

Description of the financial instrument,
type of instrument,

ADRs

 

Identification code

NVO

b)

Nature of the transaction

Purchase of ADRs

c)







Price(s) and volume(s)







 

 

 

 

 

Price(s)

Volume(s)

 

 

DKK 1,275.49

10.42 ADRs

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



10.42 ADRs
DKK 1,275.49

e)

Date of the transaction

2023-09-01

f)

Place of the transaction

New York Stock Exchange


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Martin Holst Lange

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Other transaction (transfer of shares in
accordance with Long Term Incentive programme)

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 0.00

16,780 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



16,780 shares
DKK 0.00

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Outside a trading venue

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Martin Holst Lange

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Other transaction (transfer of shares in
accordance with Long Term Incentive programme)

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 0.00

33,600 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



33,600 shares
DKK 0.00

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Outside a trading venue

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Tania Sabroe

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Other transaction (transfer of shares in
accordance with Long Term Incentive programme)

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 0.00

7,763 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



7,763 shares
DKK 0.00

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Outside a trading venue

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Tania Sabroe

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Other transaction (transfer of shares in
accordance with Long Term Incentive programme)

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 0.00

13,220 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



13,220 shares
DKK 0.00

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Outside a trading venue

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Tania Sabroe

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Sale of shares

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 756.84

413 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



413 shares
DKK 756.84

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Nasdaq Copenhagen

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Tania Sabroe

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Sale of shares

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 756.84

702 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



702 shares
DKK 756.84

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Nasdaq Copenhagen

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Marcus Schindler

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Other transaction (transfer of shares in
accordance with Long Term Incentive programme)

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 0.00

16,780 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



16,780 shares
DKK 0.00

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Outside a trading venue

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Marcus Schindler

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Other transaction (transfer of shares in
accordance with Long Term Incentive programme)

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 0.00

33,600 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



33,600 shares
DKK 0.00

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Outside a trading venue

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Camilla Sylvest

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Other transaction (transfer of shares in
accordance with Long Term Incentive programme)

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 0.00

41,254 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



41,254 shares
DKK 0.00

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Outside a trading venue

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Camilla Sylvest

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Other transaction (transfer of shares in
accordance with Long Term Incentive programme)

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 0.00

43,402 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



43,402 shares
DKK 0.00

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Outside a trading venue

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Henrik Ehlers Wulff

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Other transaction (transfer of shares in
accordance with Long Term Incentive programme)

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 0.00

43,563 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



43,563 shares
DKK 0.00

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Outside a trading venue

 


1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board member/Executive/Associated Person

Henrik Ehlers Wulff

 

2

Reason for the notification

 

a)

Position/status

Executive Vice President

 

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer

 

a)

Name

Novo Nordisk A/S

 

b)

LEI

549300DAQ1CVT6CXN342

 

4

Details of the transaction(s)

 

a)

Description of the financial instrument,
type of instrument,

Shares

 

 

Identification code

Novo Nordisk B DK0062498333

 

b)

Nature of the transaction

Other transaction (transfer of shares in
accordance with Long Term Incentive programme)

 

c)







Price(s) and volume(s)







 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

DKK 0.00

45,834 shares

 

 

 

 

 

 

 

 

 

 

 

 

d)

Aggregated information

  • Aggregated volume

  • Price



45,834 shares
DKK 0.00

 

e)

Date of the transaction

2024-01-31

 

f)

Place of the transaction

Outside a trading venue

 

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:

 

Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com

Elizabeth DeLuca (US)
+1 609 580 9868
edel@novonordisk.com

Investors:

 

Daniel Muusmann Bohsen
+45 3075 2175
dabo@novonordisk.com

Frederik Taylor Pitter
+45 3075 8259 fptr@novonordisk.com

David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com

Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com

Sina Meyer
+45 3079 6656 azey@novonordisk.com

 

Company Announcement No 8 / 2024

Attachment